Previous close | 245.37 |
Open | 245.17 |
Bid | 244.85 x 1400 |
Ask | 246.72 x 800 |
Day's range | 244.02 - 246.29 |
52-week range | 198.64 - 258.45 |
Volume | |
Avg. volume | 3,298,398 |
Market cap | 130.799B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 24.19 |
EPS (TTM) | 10.12 |
Earnings date | 01 Aug 2022 - 05 Aug 2022 |
Forward dividend & yield | 7.76 (3.25%) |
Ex-dividend date | 16 May 2022 |
1y target est | 250.03 |
Let's look at two companies that fit the bill: Amgen (NASDAQ: AMGN) and Microsoft (NASDAQ: MSFT). Biotech Amgen has been around since 1980, and in that time the company has survived several recessions. In the first quarter, Amgen's revenue increased by a respectable 6% year over year to $6.2 billion.
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
In the latest trading session, Amgen (AMGN) closed at $234.72, marking a +1.74% move from the previous day.